Aquestive Therapeutics (NASDAQ:AQST) Now Covered by Analysts at Oppenheimer

Stock analysts at Oppenheimer began coverage on shares of Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) in a research report issued on Monday, Marketbeat.com reports. The firm set an "outperform" rating and a $7.00 price target on the stock. Oppenheimer's price objective would indicate a potential upside of 120.13% from the stock's previous close.

A number of other equities research analysts also recently issued reports on AQST. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Thursday, May 15th. Alliance Global Partners reiterated a "buy" rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Raymond James set a $7.00 price target on Aquestive Therapeutics in a research note on Friday, March 7th. Finally, Lake Street Capital cut their price objective on Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Friday, March 7th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Aquestive Therapeutics has a consensus rating of "Buy" and an average price target of $10.14.

Aquestive Therapeutics Stock Performance

AQST stock traded up $0.37 during midday trading on Monday, reaching $3.18. 2,094,095 shares of the company traded hands, compared to its average volume of 1,513,977. Aquestive Therapeutics has a 52-week low of $2.12 and a 52-week high of $5.80. The business has a 50 day moving average of $2.65 and a 200-day moving average of $3.15. The firm has a market capitalization of $315.86 million, a price-to-earnings ratio of -7.07 and a beta of 2.02.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07). The business had revenue of $8.72 million during the quarter, compared to analyst estimates of $12.23 million. Research analysts anticipate that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

Institutional Trading of Aquestive Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of AQST. SG Americas Securities LLC raised its stake in shares of Aquestive Therapeutics by 28.7% during the fourth quarter. SG Americas Securities LLC now owns 32,966 shares of the company's stock valued at $117,000 after acquiring an additional 7,347 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Aquestive Therapeutics during the fourth quarter valued at approximately $69,000. Financial Advocates Investment Management raised its stake in shares of Aquestive Therapeutics by 28.2% during the fourth quarter. Financial Advocates Investment Management now owns 50,000 shares of the company's stock valued at $178,000 after acquiring an additional 11,000 shares in the last quarter. Harvey Capital Management Inc. raised its stake in shares of Aquestive Therapeutics by 1,419.3% during the fourth quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company's stock valued at $952,000 after acquiring an additional 249,790 shares in the last quarter. Finally, New York State Common Retirement Fund raised its stake in shares of Aquestive Therapeutics by 713.3% during the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company's stock valued at $43,000 after acquiring an additional 10,700 shares in the last quarter. Institutional investors own 32.45% of the company's stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.